TNF blockers alone and associated with Benznidazole impact in vitro cytokine dynamics in chronic Chagas disease
Authors:
- Diego José Lira TorresDTDiego José Lira Torres
- Kamila Kássia dos Santos OliveiraKOKamila Kássia dos Santos Oliveira
- Michelle da Silva BarrosMBMichelle da Silva Barros
- Leyllane Rafael MoreiraLMLeyllane Rafael Moreira
- Luciane de Freitas FirminoLFLuciane de Freitas Firmino
- Maria da Glória Aureliano Melo CavalcanteMCMaria da Glória Aureliano Melo Cavalcante
- Sílvia Marinho MartinsSMSílvia Marinho Martins
- Wilson Alves de Oliveira JuniorWJWilson Alves de Oliveira Junior
- Michelle Christiane da Silva RabelloMRMichelle Christiane da Silva Rabello
- Virginia Maria Barros de LorenaVLVirginia Maria Barros de Lorena
- 22 February 2024
- journal article
- research article
- Published by Wiley in Parasite Immunology
- Vol. 46 (2) , e13024
Abstract
Studies involving the immune response in Chagas disease suggest an imbalance in the immune response of symptomatic patients, with an inflammatory profile dominating in Chagas heart disease, mainly by tumour necrosis factor (TNF). TNF is considered a key cytokine in immunopathology in chronic carriers in several processes during the immune response. Our work aimed to evaluate regulatory (interleukin [IL]‐4 and IL‐10) and inflammatory (TNF, interferon‐gamma [IFN‐γ], IL‐2 and IL‐6) cytokines in peripheral blood mononuclear cells culture supernatants. of affected patients with undetermined clinical forms—IND (n = 13) mild heart form—CARD1 (n = 13) and severe cardiac form—CARD2 (n = 16), treated in vitro with two TNF blockers, Adalimumab (ADA) and Etanercept (ETA) alone or in association with Benznidazole (BZ). The results indicate that ADA was more competent in blocking TNF (compared to ETA) in all groups but with much lower levels in the CARD2 group. ETA statistically decreased TNF levels only in the CARD2 group. IFN‐γ increased in the CARD2 group after treatment with ETA relative to ADA. IL‐4 had its levels decreased when treated by both drugs. IL‐2 was detected in cells from CARD2 carriers compared to the NEG group after treatment with both drugs. The association with BZ decreased levels of IL‐2/TNF and increased IL‐4. These data reinforce the participation of TNF in severe Chagas heart disease and bring perspectives on using these blockers in the immunological treatment of Chagas disease since the use of BZ is extremely limited in these patients.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (474926/212‐5‐Universal)
This publication has 37 references indexed in Scilit:
- Is a negative correlation between sTNFR1 and TNF in patients with chronic Chagas disease the key to clinical progression?Immunobiology, 2022
- Chagas Disease: Chronic Chagas CardiomyopathyCurrent Problems in Cardiology, 2021
- Benznidazole: Hero or villain of cellular immune response in chronic Chagas disease patients?Immunobiology, 2021
- Plasma levels of soluble TNF receptors are associated with cardiac function in patients with Chagas heart diseaseInternational Journal of Cardiology, 2020
- Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strainInternational Journal for Parasitology: Drugs and Drug Resistance, 2016
- Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas diseaseInternational Journal of Cardiology, 2015
- Etiological treatment of Chagas disease patients with benznidazole lead to a sustained pro-inflammatory profile counterbalanced by modulatory eventsImmunobiology, 2015
- IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiationCurrent Opinion in Immunology, 2011
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registryArthritis & Rheumatism, 2009
- Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIAcoreAnalytical Biochemistry, 2001